 |
Orthopedic
Industry Supplier News |
| Return to Supplier News Source: Ionbond is pleased to announce the completion of its planned divestiture from Saurer and the global expansion of the Ionbond Medical Business Unit, Medthin. Olten, July 2004 - Ionbond is pleased to announce that its planned divestiture from Saurer has now been completed. The divestiture was accomplished through a buyout by Stirling Square Capital Partners (SSCP), a British private equity fund, together with Ionbond management. The new ownership structure accounts for 100% ownership of the stock of the company and underscores management commitment to the business, which has experienced healthy growth over the past three years. The company’s coating centers, located in the USA, Canada, Switzerland, England, Singapore and Thailand will be maintained, as well as the headquarters in Olten, Switzerland. The independent structure will allow Ionbond to operate with increased flexibility and vision in a highly innovative market. As the pioneer of commercial hard coatings for the medical device industry, a primary focus of the company will be the worldwide expansion of this coating business as related to orthopaedic and dental implants, surgical and dental instruments, and other associated medical and orthodontic devices. With the introduction of Medthin, a special unit with dedicated people, processes and biocompatible coatings, we have integrated our extensive experience in thin film coatings with the demanding quality and performance standards of the medical and dental industries. For further information: Gene Elwood |